Inagene Diagnostics Inc. and Granville Biomedical Inc. team up to provide locally-produced pharmacogenetic testing kits to Canadians

Inagene Diagnostics Inc.和Granville Biomedical Inc.合作向加拿大人提供本地生产的药物遗传学检测试剂盒

2021-11-01 21:30:03 BioSpace

本文共1513个字,阅读需4分钟

Partnership will provide Canadians access to the powerful benefits of personalized medicine while strengthening a new Canadian supply chain. TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Canadian pharmacogenetic (PGx) testing provider, Inagene Diagnostics Inc., has partnered with fellow Canadian health-tech company, Granville Biomedical Inc., to add Canadian researched and developed medical grade swabs to its testing kits, bringing the best of locally manufactured medical products to Canadians. Inagene Diagnostics Inc.’s PGx test is conducted using an oral cheek (buccal) swab that analyzes a person’s DNA to determine which medications are most compatible for the individual according to their genetic profile. Granville Biomedical Inc., a company specializing in the design of novel medical devices, recently expanded their business to include the research and development of medical grade swabs following the Canadian government’s call at the onset of the pandemic for assistance to produce Made in Canada COVID-19 testing supplies. The funding opportunities that followed, allowed Granville to quickly redirect their efforts from women’s health to the production of Class 1, Canadian-made medical devices. The development of Granville Swab™ also resulted in the creation of a robust domestic supply chain in Canada that Canadian organizations, such as Inagene, can leverage. To align with their Toronto-based lab location, Inagene is committed to promoting Made in Canada quality by continuing to improve their testing kits, with a goal to make the kit a 100% Canadian product by 2022. "Our Granville team is very inspired by the work that Inagene Diagnostics is doing within the pharmacogenetic testing space, and we are honoured to engage in this collaboration for the purpose of advancing Canadian healthcare,” said Christine Goudie, CEO of Granville Biomedical. “This partnership will foster our domestic supply chain as well as encourage and promote future made-in-Canada healthcare supplies.” Granville Biomedical is currently working on the development and validation of a uniquely designed oral swab for Inagene to include in their genetic testing kits. The focus of the novel swab is to ensure specimen collection efficacy comparable to existing market leading buccal swabs. The swab will be validated through Health Canada and their associated Class 1 regulatory requirements. Inagene Diagnostics Inc. was founded to help people with pain and mental health conditions, find more effective treatment, faster. Research shows that 98% of Canadians carry genetic variants that can impact a person’s response to various medications. PGx testing provides valuable insights that allow patients to determine which medication is predicted to work most effectively for them, with the least side effects. “PGx testing can have a life-changing impact on those living with chronic illnesses,” says Nancy White, CEO of Inagene Diagnostics Inc. “We’re proud to have such a strong innovation partner in the Canadian medical products space, who shares our passion for helping people, to bring the best possible product to Canadians, and support the Canadian healthcare ecosystem.” About Inagene Diagnostics Inc. Inagene™ Diagnostics Inc. is a CLIA accredited Canadian pharmacogenetic testing company located in Toronto. Inagene’s Personalized Insights™ tests focus on providing comprehensive and reliable genetic tests to guide drug selection and treatment. Learn more at www.inagene.com ​​About Granville Biomedical Granville Biomedical Inc. is a Canadian health-tech company specializing in the design of innovative medical devices and anatomical teaching tools to enhance healthcare training and delivery. Hailing from St. John’s, the company’s Granville Swab™ launched in 2020 for Covid-19 testing purposes, followed by the research and development of a novel oral buccal swab. Learn more at www.granvillebiomedical.ca and www.granvilleswab.ca. Note to Editors: For further information, please contact: Neelam Bance Parsons, Inagene Diagnostics nbanceparsons@inagene.com
合作伙伴关系将为加拿大人提供个性化医疗的强大好处,同时加强加拿大新的供应链。 多伦多,2021年11月1日(环球新闻)--加拿大药物遗传学(PGx)检测提供商Inagene Diagnostics Inc.与加拿大卫生技术公司Granville Biomedical Inc.合作,在其检测试剂盒中添加加拿大研究和开发的医疗级拭子,为加拿大人带来最好的本地制造的医疗产品。 Inagene Diagnostics Inc.的PGx测试是使用口腔颊拭子进行的,该拭子分析一个人的DNA,根据他们的基因特征确定哪些药物最适合个人。格兰维尔生物医学公司(Granville Biomedical Inc.)是一家专门设计新型医疗设备的公司,最近将业务扩大到包括医疗级拭子的研究和开发,此前加拿大政府在疫情爆发时呼吁帮助生产加拿大制造的新冠肺炎测试用品。随后的融资机会使格兰维尔迅速将他们的努力从妇女健康转向生产1类加拿大制造的医疗设备。Granville拭子™的开发也导致了加拿大国内供应链的建立,加拿大组织,如Inagene,可以利用这一供应链。为了配合他们位于多伦多的实验室位置,Inagene致力于通过继续改进他们的测试试剂盒来提高加拿大制造的质量,目标是到2022年使试剂盒100%成为加拿大产品。 Granville Biomedical首席执行官Christine Goudie说:“Inagene Diagnostics在药物遗传学测试领域所做的工作给我们的Granville团队带来了很大的启发,我们很荣幸能参与这项合作,以促进加拿大的医疗保健。这项合作将促进我们国内的供应链,并鼓励和促进未来加拿大制造的医疗保健用品。” Granville Biomedical目前正在开发和验证一种独特设计的口腔拭子,用于Inagene的基因检测试剂盒。新型拭子的重点是确保标本采集效果与现有市场领先的颊拭子相当。棉签将通过加拿大卫生部及其相关的1类法规要求进行验证。 Inagene Diagnostics公司的成立是为了帮助患有疼痛和精神健康问题的人,找到更有效、更快的治疗方法。研究表明,98%的加拿大人携带基因变异,这些变异会影响一个人对各种药物的反应。PGx测试提供了有价值的见解,使患者能够确定哪种药物对他们最有效,副作用最小。 “PGX测试可以对慢性病患者产生改变生活的影响,”Inagene Diagnostics Inc.首席执行官南希·怀特(Nancy White)表示。“我们很自豪在加拿大医疗产品领域有这样一个强大的创新合作伙伴,他们与我们分享帮助人们的热情,为加拿大人带来最好的产品,并支持加拿大医疗保健生态系统。” 关于Inagene诊断公司。 Inagene™诊断公司是一家经CLIA认证的加拿大药物遗传学检测公司,位于多伦多市。Inagene的个性化Insights™测试专注于提供全面可靠的基因测试,以指导药物选择和治疗。在www.inagene.com了解更多信息 关于格兰维尔生物医学 Granville Biomedical Inc.是一家加拿大医疗技术公司,专门从事创新医疗设备和解剖学教学工具的设计,以加强医疗保健培训和交付。该公司的格兰维尔拭子™来自圣约翰,于2020年推出,用于新冠肺炎测试,随后研发了一种新型口腔颊拭子。在www.granvillebiomedical.ca和www.granvilleswab.ca了解更多信息。 编辑注意: 如需进一步资料,请联络: 尼拉姆·班斯·帕森斯,Inagene诊断学 nbanceparsons@inagene.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文